GlobeNewswire Inc.··NaIN8bio to Unveil Gamma-Delta T Cell Advances at May R&D Day
IN8bio showcases gamma-delta T cell advances and glioblastoma survival data at May 2026 R&D Day and major medical conferences.
INABclinical dataautoimmune diseases
glioblastoma
7 articlesGlobeNewswire Inc.··Na
Benzinga··PrnewswireNWBO Bolsters Leadership With Veteran Pharma Executive to Expand Cancer Vaccine Platform
Northwest Biotherapeutics appoints experienced biopharma executive Dr. Annalisa Jenkins as Strategic Adviser to advance its DCVax dendritic cell cancer vaccine platform.
NWBOpersonalized medicinesolid tumors
Benzinga··PrnewswireNorthwest Biotherapeutics Opens Dedicated UK Clinic to Scale Immunotherapy Production
Northwest Biotherapeutics establishes dedicated UK leukapheresis clinic by June 2026, enabling scaled immunotherapy production and removing manufacturing bottlenecks.
NWBOpersonalized medicineglioblastoma
GlobeNewswire Inc.··Portnoy Law FirmImmunityBio Faces Class Action After Failed Trial Triggers 12% Stock Plunge
Portnoy Law Firm launches class action against $IMNB following failed Phase 2 glioblastoma trial, citing investor losses from steep stock decline.
IBRXclass action lawsuitinvestor losses
GlobeNewswire Inc.··Trogenix Ltd.Trogenix Gene Therapy Achieves Complete Tumor Eradication in Glioblastoma Study
Trogenix publishes Nature data showing 83% complete tumor elimination in aggressive brain cancer model. Phase I/II trial dosing planned for Q2 2026.
LLYclinical trialgene therapy
GlobeNewswire Inc.··NaAdaptin Bio Gains OTCQB Listing as Glioblastoma Drug Enters Clinical Trials
Adaptin Bio ($APTN) approved for OTCQB quotation. Lead program APTN-101, a brain bispecific T cell engager for glioblastoma, receives FDA clearance for Phase 1 trials.
APTNPhase 1 clinical trialglioblastoma
The Motley Fool··James HalleyTelix Pharmaceuticals Eyes Growth With Nuclear Medicine Expansion
Telix Pharmaceuticals expands its nuclear medicine presence with approved cancer-targeting drugs and 56% revenue growth, positioning itself as a key player in oncology diagnostics and therapeutics.
TLXbiotechradiopharmaceuticals